By Helen Christophi ( January 16, 2013, 6:52 PM EST) -- A Hemispherx Biopharma Inc. shareholder hit the drugmaker and its executives with a derivative suit in Pennsylvania federal court Tuesday, accusing the company of lying about the safety and efficacy of its chronic fatigue syndrome drug, which annihilated its stock price after the medication's study results were questioned....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.